Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jan
09
Today In Oncology
ACS Guidelines for Cervical Cancer Self-Collected HPV Testing Now Included
Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL
Prostate Cancer: Novel PSMA-Targeted Radioligand Shows Reduced Salivary Gland Uptake in Preclinical Studies
CD123-Targeting ADC Shows Activity in AML and BPDCN
New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo